Takeda

Q: Where are Takeda’s headquarters?

Takeda’s headquarters are in 1-1, Nihonbashi-Honcho 2-chome,, Tokyo, Japan

Q: What is Takeda’s phone number?

Takeda’s phone number is +81 3-3278-2000

Q: What is Takeda’s stock symbol?

Takeda’s stock symbol is 4502

Q: What is Takeda’s official website?

Takeda’s official website is www.takeda.com

Q: What is Takeda’s Revenue?

Takeda’s revenue is $26 Billion

Q: What is Takeda’s industry?

Takeda is in the industry of: Manufacturing , Pharmaceuticals

Q: Who are Takeda’s main competitors?

Takeda's main competitors are: Shionogi & Co. , Ltd. , Astellas Pharma Inc. , Forest Laboratories , Inc. , Eli Lilly and Company

Q: What companies has Takeda acquired?

Takeda has acquired the companies: Adaptate Biotherapeutics, GammaDelta Therapeutics, Nycomed Pharma, BIKAM Pharmaceuticals

Q: What is Takeda's tech stack?

The technologies that are used by Takeda are: D3.js, Amazon Glacier, Cisco Meraki, Snowflake

Q: Who is Takeda's CEO?

Takeda's CEO is Christophe Weber

Manufacturing · Japan · 47,495 Employees

Get Full Access

Who is Takeda

Founded in 1781, Takeda Pharmaceutical Company engages in the research, development, manufacturing, and marketing of pharmaceutical products, over-the-counter medicines and quasi-drug consumer products, and other healthcare products. It offers pharmaceutical products in the areas of gastroenterology; oncology; neuroscience; and rare diseases, such as rare metabolic and hematology, and heredity angioedema, as well as plasma-derived therapies and vaccines. The company is headquartered in Tokyo, JapanRead More

Headquarters:

1-1, Nihonbashi-Honcho 2-chome,, Tokyo, Japan

Phone Number:

+81 3-3278-2000

Website:

www.takeda.com

Revenue:

$26 Billion

Stock Symbol:

4502

Is this data correct?

View contact profiles from Takeda

SIC Code 28,283

NAICS Code 325414,32541

Ticker TYO: 4502

Top Competitors of Takeda

Shionogi & Co. , Ltd.

5,511

$3 Billion

Astellas Pharma Inc.

17,202

$11 Billion

Forest Laboratories , Inc.

6,200

$3 Billion

Eli Lilly and Company

40,655

$22 Billion

LEO Pharma Inc

4,189

Amneal Pharmaceuticals LLC

6,500

Takeda's Org Chart

Christophe Weber

Representative Director, President ...

Phone

Valerie Tan

Chief Marketing Officer, Sqm Qualit...

Phone

Sue Evans

Chief Technology Officer, Team

Phone

Takeda Email Formats

Takeda uses at least 5 email formats with first.last (ex. John.Smith@takeda.com) being used 59.2% of the time

Get Verified Emails

Takeda Email Formats		Percentage
first.last	John.Smith@takeda.com	59.2%
first.last	John.Smith@shire.com	19.8%
first + last	JohnSmith@takeda.com	0%
first_last	John_Smith@takeda.com	0%
first	John@takeda.com	0%

View Email Formats for Takeda

Takeda Company Metrics

Company Insights

Employee Growth Rate

Revenue

Quarter	Revenue
'21 - Q1	18801712000
'21 - Q2	18801712000

Acquisitions & Subsidiaries

May 05, 2020

Adaptate Biotherapeutics

Apr 05, 2018

GammaDelta Therapeutics

Nov 01, 2017

Nycomed Pharma

Aug 20, 2016

BIKAM Pharmaceuticals

Jan 26, 2016

Baxalta

Sep 11, 2015

Coretherapix

See More Acquisitions & Subsidiaries

Takeda's Tech Stack

D3.js

The D3.js

Amazon Glacier

Amazon.com

Cisco Meraki

Cisco

Snowflake

See more technologies

Takeda News & Media

Takeda's Hereditary Angioedema Treatment Prevents Attacks In Kids Below 12 Years

Takeda Pharmaceutical Co Ltd (NYSE: TAK) announced late-breaking data from the Phase 3 SPRING study presented at the European Academy of Allergy and Clinical Immunology Hybrid Congress 2022. read more

Takeda’s TAKHZYRO® (lanadelumab) Demonstrated Positive Results in the Prevention of HAE Attacks in First and Only Open-Label Phase 3 Trial in Children Ages 2 to <12 Years

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced late-breaking data from the Phase 3 SPRING study (NCT04070326) presented at the European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress 2022, demonstrating positive results of TAKHZYRO® (lanadelumab) for preventing hereditary angioedema (HAE) attacks in patients 2 to <12 years of age, which were consistent with earlier studies in adult and adolescent patients.1 There are currently

Results from Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency Published in New England Journal of Medicine

OSAKA, Japan & PASADENA, Calif.--(BUSINESS WIRE)--Results from Phase 2 Study of fazirsiran in patients with alpha-1 antitrypsin deficiency published in New England Journal of Medicine.